Omeros Corporation
OMER Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Income
Balance Sheet
Cash Flow
OMER Income Statement
OMER Balance Sheet
OMER Cash Flow
Recent trades of OMER by members of U.S. Congress
OMER Stock Insider Trading Activity
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
OMER Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
OMER Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by OMER's directors and management
Government lobbying spending instances
-
$45,000 Oct 24, 2024 Issue: Medicare/Medicaid
-
$60,000 Oct 21, 2024 Issue: Health Issues
-
$80,000 Oct 21, 2024 Issue: Budget/Appropriations Medicare/Medicaid
-
$45,000 Oct 18, 2024 Issue: Medicare/Medicaid
-
$75,000 Oct 14, 2024 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$80,000 Oct 10, 2024 Issue: Medicare/Medicaid
-
$45,000 Aug 12, 2024 Issue: Medicare/Medicaid
-
$80,000 Jul 22, 2024 Issue: Budget/Appropriations Medicare/Medicaid
-
$60,000 Jul 22, 2024 Issue: Health Issues
-
$75,000 Jul 19, 2024 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$80,000 Jul 18, 2024 Issue: Medicare/Medicaid
-
$45,000 Jul 15, 2024 Issue: Medicare/Medicaid
-
$60,000 Apr 22, 2024 Issue: Health Issues
-
$80,000 Apr 22, 2024 Issue: Medicare/Medicaid
-
$45,000 Apr 21, 2024 Issue: Medicare/Medicaid
-
$45,000 Apr 20, 2024 Issue: Medicare/Medicaid
-
$80,000 Apr 17, 2024 Issue: Medicare/Medicaid
-
$75,000 Apr 14, 2024 Issue: Medical/Disease Research/Clinical Labs
-
$60,000 Jan 22, 2024 Issue: Health Issues
-
$45,000 Jan 22, 2024 Issue: Medicare/Medicaid
-
$80,000 Jan 22, 2024 Issue: Health Issues Medicare/Medicaid
-
$45,000 Jan 22, 2024 Issue: Medicare/Medicaid
-
$80,000 Jan 20, 2024 Issue: Medicare/Medicaid
-
$75,000 Jan 11, 2024 Issue: Medical/Disease Research/Clinical Labs
-
$60,000 Oct 20, 2023 Issue: Health Issues
-
$80,000 Oct 20, 2023 Issue: Medicare/Medicaid
-
$45,000 Oct 20, 2023 Issue: Medicare/Medicaid
-
$45,000 Oct 19, 2023 Issue: Medicare/Medicaid
-
$80,000 Oct 18, 2023 Issue: Medicare/Medicaid
-
$75,000 Oct 02, 2023 Issue: Medical/Disease Research/Clinical Labs
-
$45,000 Jul 20, 2023 Issue: Medicare/Medicaid
-
$60,000 Jul 20, 2023 Issue: Health Issues
-
$80,000 Jul 20, 2023 Issue: Medicare/Medicaid
-
$45,000 Jul 19, 2023 Issue: Medicare/Medicaid
-
$80,000 Jul 13, 2023 Issue: None
-
$80,000 Apr 20, 2023 Issue: Medicare/Medicaid
-
$45,000 Apr 20, 2023 Issue: Medicare/Medicaid
-
$60,000 Apr 20, 2023 Issue: Medicare/Medicaid
-
$45,000 Apr 18, 2023 Issue: Medicare/Medicaid
-
$80,000 Apr 18, 2023 Issue: Medicare/Medicaid
-
$80,000 Apr 11, 2023 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$45,000 Feb 23, 2023 Issue: Medicare/Medicaid
-
$60,000 Feb 19, 2023 Issue: Health Issues
-
$45,000 Jan 20, 2023 Issue: Medicare/Medicaid
-
$80,000 Jan 20, 2023 Issue: Health Issues Medicare/Medicaid
-
$80,000 Jan 20, 2023 Issue: Medicare/Medicaid
-
$80,000 Jan 13, 2023 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$45,000 Nov 02, 2022 Issue: Medicare/Medicaid
-
$60,000 Oct 20, 2022 Issue: Health Issues
-
$80,000 Oct 20, 2022 Issue: Health Issues Medicare/Medicaid
-
$45,000 Oct 19, 2022 Issue: Medicare/Medicaid
-
$80,000 Oct 18, 2022 Issue: Medicare/Medicaid
-
$80,000 Oct 08, 2022 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$60,000 Jul 20, 2022 Issue: Health Issues
-
$45,000 Jul 20, 2022 Issue: Medicare/Medicaid
-
$80,000 Jul 20, 2022 Issue: Health Issues Medicare/Medicaid
-
$45,000 Jul 20, 2022 Issue: Medicare/Medicaid
-
$80,000 Jul 18, 2022 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$80,000 Jul 18, 2022 Issue: Government Issues Medicare/Medicaid
-
$60,000 Apr 20, 2022 Issue: Health Issues
-
$80,000 Apr 20, 2022 Issue: Health Issues Medicare/Medicaid
-
$45,000 Apr 20, 2022 Issue: Medicare/Medicaid
-
$45,000 Apr 20, 2022 Issue: Medicare/Medicaid
-
$80,000 Apr 12, 2022 Issue: Government Issues Medicare/Medicaid
-
$80,000 Apr 10, 2022 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$45,000 Feb 09, 2022 Issue: Medicare/Medicaid
-
$60,000 Jan 20, 2022 Issue: Health Issues
-
$45,000 Jan 20, 2022 Issue: Medicare/Medicaid
-
$80,000 Jan 19, 2022 Issue: Medicare/Medicaid Health Issues
-
$80,000 Jan 17, 2022 Issue: Government Issues Medicare/Medicaid
-
$80,000 Jan 16, 2022 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Health Issues
-
$60,000 Oct 20, 2021 Issue: Health Issues
-
$45,000 Oct 20, 2021 Issue: Medicare/Medicaid
-
$80,000 Oct 20, 2021 Issue: Medicare/Medicaid Health Issues
-
$70,000 Oct 20, 2021 Issue: Medical/Disease Research/Clinical Labs Health Issues Medicare/Medicaid
-
$80,000 Oct 20, 2021 Issue: Government Issues Medicare/Medicaid
-
$45,000 Oct 19, 2021 Issue: Medicare/Medicaid
-
$45,000 Jul 21, 2021 Issue: Medicare/Medicaid
-
$80,000 Jul 20, 2021 Issue: Medicare/Medicaid Health Issues
-
$60,000 Jul 20, 2021 Issue: Health Issues
-
$22,500 Jul 20, 2021 Issue: Medicare/Medicaid
-
$80,000 Jul 18, 2021 Issue: Medicare/Medicaid Government Issues
-
$70,000 Jul 17, 2021 Issue: Medicare/Medicaid Health Issues Medical/Disease Research/Clinical Labs
-
$45,000 Apr 20, 2021 Issue: Medicare/Medicaid
-
$60,000 Apr 20, 2021 Issue: Health Issues
-
$80,000 Apr 20, 2021 Issue: Health Issues Medicare/Medicaid
-
$60,000 Apr 19, 2021 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid
-
$22,500 Apr 16, 2021 Issue: Medicare/Medicaid
-
$80,000 Apr 16, 2021 Issue: Medicare/Medicaid
-
$60,000 Jan 21, 2021 Issue: Health Issues
-
$22,500 Jan 21, 2021 Issue: Medicare/Medicaid
-
$80,000 Jan 21, 2021 Issue: Medicare/Medicaid Health Issues
-
$80,000 Jan 20, 2021 Issue: Medicare/Medicaid
-
$45,000 Jan 20, 2021 Issue: Medicare/Medicaid
-
$50,000 Jan 16, 2021 Issue: Medical/Disease Research/Clinical Labs Health Issues Medicare/Medicaid
-
$50,000 Dec 08, 2020 Issue: Medical/Disease Research/Clinical Labs Health Issues Medicare/Medicaid
-
$60,000 Oct 20, 2020 Issue: Health Issues
-
$80,000 Oct 20, 2020 Issue: Health Issues Medicare/Medicaid
-
$22,500 Oct 20, 2020 Issue: Medicare/Medicaid
-
$45,000 Oct 19, 2020 Issue: Medicare/Medicaid
Estimated quarterly lobbying spending
U.S. Patents
New patents grants
-
Patent Title: Monoclonal antibodies, compositions and methods for detecting complement factor d Oct. 29, 2024
-
Patent Title: Masp-2 inhibitors and methods of use Oct. 08, 2024
-
Patent Title: Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof Sep. 17, 2024
-
Patent Title: Masp-2 inhibitors and methods of use Jul. 09, 2024
-
Patent Title: Methods for treating conditions associated with masp-2 dependent complement activation May. 14, 2024
-
Patent Title: Methods for inhibiting angiogenesis in a subject in need thereof May. 14, 2024
-
Patent Title: Chimeric inhibitor molecules of complement activation Apr. 02, 2024
-
Patent Title: Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant Feb. 13, 2024
-
Patent Title: Methods for treating conditions associated with masp-2 dependent complement activation Jan. 30, 2024
-
Patent Title: Antibodies specifically binding to masp-3 for the treatment of various diseases and disorders Jan. 30, 2024
-
Patent Title: Masp-2 inhibitors and methods of use Nov. 07, 2023
-
Patent Title: Masp-2 inhibitors and methods of use May. 30, 2023
-
Patent Title: Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods Apr. 18, 2023
-
Patent Title: Compositions for inhibiting masp-2 dependent complement activation Mar. 28, 2023
-
Patent Title: Masp-2 inhibitors and methods of use Feb. 21, 2023
-
Patent Title: Methods of inhibiting masp-2-dependent complement activation in a subject suffering from catastrophic antiphospholipid syndrome Dec. 13, 2022
-
Patent Title: Treatment of addiction and impulse-control disorders using pde7 inhibitors Oct. 11, 2022
-
Patent Title: Chimeric inhibitor molecules of complement activation Sep. 27, 2022
-
Patent Title: Compositions and methods for prophylaxis and treatment of addictions Feb. 08, 2022
-
Patent Title: Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions Feb. 01, 2022
-
Patent Title: Treatment of addiction and impulse-control disorders using pde7 inhibitors Dec. 28, 2021
-
Patent Title: Masp isoforms as inhibitors of complement activation Dec. 21, 2021
-
Patent Title: Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same Jun. 29, 2021
-
Patent Title: Antibodies specifically binding to masp-3 for the treatment of various diseases and disorders Jun. 08, 2021
-
Patent Title: Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant May. 25, 2021
-
Patent Title: Chimeric inhibitor molecules of complement activation Aug. 25, 2020
-
Patent Title: Nucleic acids encoding antibodies specifically binding to masp-3 Aug. 18, 2020
-
Patent Title: Methods for inhibiting fibrosis in a subject in need thereof Aug. 11, 2020
-
Patent Title: Compositions for inhibiting masp-2 dependent complement activation Jun. 16, 2020
-
Patent Title: Antibodies specifically binding to masp-3 for the treatment of various diseases and disorders May. 05, 2020
-
Patent Title: Chimeric inhibitor molecules of complement activation May. 21, 2019
-
Patent Title: G protein coupled receptor 85 and sreb3 knockout mice and uses thereof May. 21, 2019
-
Patent Title: Methods for treating conditions associated with masp-2 dependent complement activation Feb. 12, 2019
-
Patent Title: Pde10 inhibitors and related compositions and methods Oct. 23, 2018
-
Patent Title: Compositions and methods for prophylaxis and treatment of addictions Sep. 04, 2018
-
Patent Title: Compositions for inhibiting masp-2 dependent complement activation Aug. 14, 2018
-
Patent Title: Solid state forms of a pde10 inhibitor Mar. 20, 2018
-
Patent Title: Pde10 inhibitors and related compositions and methods Jan. 30, 2018
-
Patent Title: Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures Jan. 02, 2018
-
Patent Title: Stable preservative-free mydriatic and anti-inflammatory solutions for injection Jan. 02, 2018
-
Patent Title: Optically active pde10 inhibitor Dec. 26, 2017
-
Patent Title: Chimeric inhibitor molecules of complement activation Nov. 14, 2017
-
Patent Title: Pde10 inhibitors and related compositions and methods Oct. 10, 2017
-
Patent Title: Anti-fzd10 monoclonal antibodies and methods for their use Oct. 03, 2017
-
Patent Title: Composition and method for diversification of target sequences Jun. 13, 2017
-
Patent Title: Mixed micelles May. 23, 2017
-
Patent Title: Processes and intermediates for the preparation of a pde10 inhibitor May. 16, 2017
-
Patent Title: Methods for treating conditions associated with masp-2 dependent complement activation May. 09, 2017
-
Patent Title: Ophthalmologic irrigation solutions and method Mar. 07, 2017
-
Patent Title: Optically active pde10 inhibitor Nov. 15, 2016
Government Contracts
Federal grants, loans, and purchases
Government Contracts
Estimated quarterly amount awarded from public contracts
WallStreetBets
Number of mentions of OMER in WallStreetBets Daily Discussion
OMER News
Recent insights relating to OMER
CNBC Recommendations
Recent picks made for OMER stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in OMER
OMER Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view OMER Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More